X4 Pharmaceuticals (XFOR) Price & Analysis

Compare

1,026 Followers

XFOR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.38 - $26.84

Previous CloseN/A

Volume769.31K

Average Volume (3M)1.40M

Market Cap

$9.32M

Enterprise Value$39.81M

Total Cash (Recent Filing)$86.95M

Total Debt (Recent Filing)$2.41M

Price to Earnings (P/E)0.7

Beta1.58

Next Earnings

Nov 06, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding5,788,745

10 Day Avg. Volume2,623,809

30 Day Avg. Volume1,395,636

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap4.27

Enterprise Value/Revenue1.27

Enterprise Value/Gross Profit1.54

Enterprise Value/Ebitda-0.39

Forecast

1Y Price Target

$7.00

Price Target Upside334.78% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering0

Bulls Say, Bears Say

Bulls Say

CommercializationXolremdi revenues demonstrate strongest quarter since launch, with $1.4M of revenue in 4Q24, up approximately 156% from $560,000 in 3Q24.

EarningsThe company reported total revenue of $28.8M, compared to the consensus estimate of $11.6M, and a net income of $0.04 per share, compared to the consensus estimated a net loss of $0.12 per share.

Strategic AgreementsX4 entered into an exclusive licensing agreement with Norgine Pharmaceuticals for the commercialization of Xolremdi in Europe, Australia, and New Zealand, with potential E.U. approval in 1H26.

Bears Say

Commercial ChallengesThe longer-than-expected time to diagnose and initiate therapy for new WHIM patients and the high commercial cost to onboard a patient are challenges faced by the company.

Market OutlookThe analyst is taking a more conservative view of the launch trajectory and commercial opportunity in WHIM syndrome, leading to lowered estimates.

X4 Pharmaceuticals News

X4 Pharmaceuticals Advances Phase 3 Study for WHIM Syndrome Treatment

X4 Pharmaceuticals (($XFOR)) announced an update on their ongoing clinical study. Study Overview: X4 Pharmaceuticals is conducting a...

8d ago

XFOR

X4 Pharmaceuticals Advances Phase 3 Study of Mavorixafor for WHIM Syndrome

X4 Pharmaceuticals (($XFOR)) announced an update on their ongoing clinical study. Study Overview: X4 Pharmaceuticals is conducting a...

10d ago

XFOR

X4 Pharmaceuticals Completes Key Study on Mavorixafor’s Drug Interaction Potential

X4 Pharmaceuticals (($XFOR)) announced an update on their ongoing clinical study. Study Overview: X4 Pharmaceuticals has completed a...

1M ago

XFOR

X4 Pharmaceuticals Completes Key Study on Mavorixafor’s Drug Interaction Potential

X4 Pharmaceuticals (($XFOR)) announced an update on their ongoing clinical study. Study Overview: X4 Pharmaceuticals recently completed a...

1M ago

XFOR

X4 Pharmaceuticals presents data from its Phase 2 trial of mavorixafor

X4 Pharmaceuticals (XFOR) announced the presentation of positive data from its completed Phase 2 trial of mavorixafor in...

2M ago

XFOR

X4 Pharmaceuticals Elects New Director at Annual Meeting

The latest announcement is out from X4 Pharmaceuticals ( ($XFOR) ). On June 9, 2025, X4 Pharmaceuticals held...

2M ago

XFOR

X4 Pharmaceuticals granted Fast Track designation for mavorixafor by FDA

X4 Pharmaceuticals (XFOR) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation to...

2M ago

XFOR

X4 Pharmaceuticals price target raised to $7 from $1.50 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on X4 Pharmaceuticals (XFOR) to $7 from $1.50 and keeps a...

3M ago

XFOR

X4 Pharmaceuticals Reports Positive Q1 2025 Results

X4 Pharmaceuticals ( ($XFOR) ) has released its Q1 earnings. Here is a breakdown of the information X4...

3M ago

XFOR

X4 Pharmaceuticals’ Earnings Call: Progress Amid Challenges

X4 Pharmaceuticals (($XFOR)) has held its Q1 earnings call. Read on for the main highlights of the call....

3M ago

XFOR

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

3M ago

NVS

ABEO

X4 Pharmaceuticals Reports Q1 2025 Financial Results

The latest update is out from X4 Pharmaceuticals ( ($XFOR) ). On May 1, 2025, X4 Pharmaceuticals reported...

3M ago

XFOR

X4 Pharmaceuticals reports Q1 EPS 4c vs. ($7.77) last year

Reports Q1 revenue $28.8M vs. $0 last year. “The first quarter of 2025 was an extremely productive and...

3M ago

XFOR

X4 Pharmaceuticals management to meet with Cantor Fitzgerald

Meeting to be held in New York on April 29 hosted by Cantor Fitzgerald. Published first on TheFly...

3M ago

XFOR

XFOR FAQ

What was X4 Pharmaceuticals’s price range in the past 12 months?

X4 Pharmaceuticals lowest stock price was $1.38 and its highest was $26.84 in the past 12 months.

What is X4 Pharmaceuticals’s market cap?

X4 Pharmaceuticals’s market cap is $9.32M.

When is X4 Pharmaceuticals’s upcoming earnings report date?

X4 Pharmaceuticals’s upcoming earnings report date is Nov 06, 2025 which is in 89 days.

How were X4 Pharmaceuticals’s earnings last quarter?

Currently, no data Available

Is X4 Pharmaceuticals overvalued?

According to Wall Street analysts X4 Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does X4 Pharmaceuticals pay dividends?

X4 Pharmaceuticals does not currently pay dividends.

What is X4 Pharmaceuticals’s EPS estimate?

X4 Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does X4 Pharmaceuticals have?

X4 Pharmaceuticals has 5,788,745 shares outstanding.

What happened to X4 Pharmaceuticals’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of X4 Pharmaceuticals?

Currently, no hedge funds are holding shares in XFOR

X4 Pharmaceuticals Stock Smart Score

Underperform

Fundamentals

Return on Equity

121.75%

Trailing 12-Months

Asset Growth

15.89%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

X4 Pharmaceuticals

X4 Pharmaceuticals, Inc. (XFOR) is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutics aimed at treating rare diseases. The company's primary focus is on diseases characterized by disruptions in immune cell trafficking, including certain types of primary immunodeficiencies. X4's lead product candidate, mavorixafor, is being developed to treat a range of conditions linked to this mechanism, such as WHIM syndrome, a rare immune disorder.

X4 Pharmaceuticals (XFOR) Earnings & Revenues

Historic Earnings Reports

XFOR Company Deck

XFOR Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlights significant progress in clinical trials and strategic partnerships for global market expansion, alongside a strong financial position. However, there are challenges in sales fluctuations and market penetration in the WHIM syndrome segment. On balance, the positive developments and growth potential outweigh the current sales challenges.View all XFOR earnings summaries